Keyphrases
Disease Survival
100%
Delayed Hypersensitivity
100%
Stage III Disease
100%
Melanoma Vaccine
100%
CTLA-4 Blockade
100%
Survival Biomarkers
100%
Ipilimumab
100%
Melanoma Cells
66%
5-year Survival
66%
Autologous Vaccine
66%
Response Rate
33%
Adjuvant Therapy
33%
Tumor
33%
Gene Signature
33%
Gene Expression Analysis
33%
Progressive Disease
33%
Poor Survival
33%
Improved Survival
33%
Gene Expression Array
33%
Unvaccinated
33%
Recurrent Disease
33%
Protective Immunity
33%
Dinitrophenyl
33%
Cancer Stage
33%
Melanoma Patients
33%
Median Overall Survival
33%
3-year Survival
33%
American Joint Committee on Cancer
33%
SSX1
33%
Cancer-testis Antigen
33%
MAGE-A
33%
Medicine and Dentistry
Biological Marker
100%
CTLA-4
100%
Delayed Hypersensitivity
100%
Melanoma Vaccine
100%
Ipilimumab
100%
Diseases
100%
Melanoma Cell
66%
Overall Survival
66%
Hypersensitivity Response
66%
Gene Expression
33%
Recurrent Disease
33%
Neoplasm
33%
Progressive Disease
33%
Gene Expression Profiling
33%
Expression Array
33%
Adjuvant Therapy
33%
2,4 Dinitrophenol
33%
Mycobacterium Bovis BCG
33%
Cancer Testis Antigen
33%
Stage 3 Cancer
33%
Melanoma
33%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Marker
100%
Melanoma
100%
Delayed Hypersensitivity
100%
Melanoma Vaccine
100%
Ipilimumab
100%
Diseases
100%
Cytotoxic T Lymphocyte Antigen 4
100%
Overall Survival
66%
Adjuvant
33%
Recurrent Disease
33%
Neoplasm
33%
Expression Array
33%
Cancer Staging
33%
2,4-Dinitrophenol
33%
Mycobacterium Bovis BCG
33%
Cancer Testis Antigen
33%
Immunology and Microbiology
CTLA-4
100%
Delayed Hypersensitivity
100%
Melanoma Vaccine
100%
Ipilimumab
100%
Melanoma Cell
66%
Overall Survival
66%
Gene Expression
33%
Adjuvant
33%
Cancer Staging
33%
Mycobacterium Bovis BCG
33%
Cancer Testis Antigen
33%
Gene Expression Assay
33%
Biochemistry, Genetics and Molecular Biology
Erethism
100%
CTLA-4
100%
Ipilimumab
100%
Overall Survival
66%
Gene Expression
33%
Gene Expression Profiling
33%
Cancer Staging
33%
Gene Signature
33%
SSX1
33%
Mycobacterium Bovis BCG
33%